An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment Possibilities

APPROVED_FOR_MARKETING

Conditions studied: Lung Diseases, Interstitial

In brief

This Expanded Access Program is intended to facilitate the availability of OFEV to patients suffering from non Idiopathic Pulmonary Fibrosis-Interstitial Lung Disease (non IPF-ILD) with a progressive clinical course despite Standard of Care treatment and for whom no satisfactory authorised alternative therapy exists or who cannot enter a clinical trial.

Key facts

Study ID

NCT03843892

Run by

Boehringer Ingelheim

Last updated by the study team

2024-12-10

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• None

You may not qualify if…

• Patients who are eligible for and can participate in an ongoing non Idiopathic Pulmonary Fibrosis-Interstitial Lung Disease (non IPF-ILD) study will be excluded from participation in this Expanded Access Program (EAP).

Where it is running

• Banner University Medical Center Tucson — Tucson, Arizona, United States
• The Lung Research Center, LLC — Chesterfield, Missouri, United States
• Glacier View Research Institute — Kalispell, Montana, United States
• University of Rochester Medical Center — Rochester, New York, United States
• Centra Medical Group — Bedford, Virginia, United States
• Inova Fairfax Medical Campus — Falls Church, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.